







an Open Access Journal by MDPI

Carcinogenesis Model

Guest Editor:

Dr. Yoshitaka Hippo

Division of Molecular Carcinogenesis, Chiba Cancer Center Research Institute, 666-2, Nitona-cho, Chuo-ku, Chiba-city, Chiba 260-8717, Japan

Deadline for manuscript submissions:

31 May 2024

Message from the Guest Editor

Dear Colleagues,

Accumulated genetic alterations can initiate and drive carcinogenesis, which are subjected to promotion by epigenetic changes through interactions with many different types of cells in the tissue microenvironment. By genetic engineering and/or chemical treatments, researchers have created many in vivo animal models, which successfully recapitulated multistep carcinogenesis from normal cells to premalignant lesions, full-blown tumors and metastases. In light of such rapid advances in the field of carcinogenesis models, we need to put together various different types of models -including those generated by conventional or novel methods- to further promote cancer research. In this special issue of Cancers, we welcome original research articles or comprehensive review articles focusing on development of, or by using, any types of models reflecting any steps of carcinogenesis, in any species or organs. I hope that such collection of studies will further increase our knowledge carcinogenesis and provide powerful tools to fight against cancer

- tumorigenesis, models
- genetically engineered mouse (GEM)
- chemical carcinogenesis













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us